@article{Lambe_T-2022_64692,
title = {SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses},
author = {Lambe, T. and Pollard, A. and Crook, D. and Webster, H. and Dunachie, S. and Barnes, E. and Klenerman, P. and Carroll, M. and Tan, T. and Huang, K. and Townsend, A. and Semple, M. and Baillie, J. and Openshaw, P. and Malik, T. and Nunes, C. and Madhi, S. and Kwatra, G. and Serafin, N. and Baillie, V. and Siqueira, M. and Pauvolid-Correa, A. and Resende, P. and Fernandes da Costa, C. and Nascimento, F. and Nascimento, V. and Naveca, F. and Costa Clemens, S. and Voysey, M. and Aley, P.},
month = {jan},
year = {2022},
abstract = {On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.},
pages = {467-484},
volume = {185},
issue = {3},
journal = {Cell},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.cell.2021.12.046},
}
